ANI Pharmaceuticals (ANIP) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

ANI Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$486.82M

Latest Revenue (Q)

$148.33M

Main Segment (Y)

Sales of generic pharmaceutical products

Main Geography (Y)

UNITED STATES

ANI Pharmaceuticals Revenue by Period

ANI Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$486.82M	53.87%
2022-12-31	$316.38M	46.38%
2021-12-31	$216.14M	3.67%
2020-12-31	$208.47M	0.93%
2019-12-31	$206.55M	2.47%
2018-12-31	$201.58M	13.99%
2017-12-31	$176.84M	37.49%
2016-12-31	$128.62M	68.53%
2015-12-31	$76.32M	36.36%
2014-12-31	$55.97M	86.06%
2013-12-31	$30.08M	1207.49%
2012-12-31	$2.30M	428.71%
2011-12-31	$435.16K	-82.41%
2010-12-31	$2.47M	96.67%
2009-12-31	$1.26M	-66.73%
2008-12-31	$3.78M	666.82%
2007-12-31	$493.05K	-96.59%
2006-12-31	$14.44M	5488.76%
2005-12-31	$258.35K	231.70%
2004-12-31	$77.89K	18.92%
2003-12-31	$65.49K	-97.69%
2002-12-31	$2.83M	62.18%
2001-12-31	$1.75M	87369200.00%
2000-12-31	$2.00	100.00%
1999-12-31	$1.00	-100.00%
1998-12-31	$123.06K	-

ANI Pharmaceuticals generated $486.82M in revenue during NA 2023, up 53.87% compared to the previous quarter, and up 241.50% compared to the same period a year ago.

ANI Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$148.33M	7.46%
2024-06-30	$138.04M	0.44%
2024-03-31	$137.43M	4.39%
2023-12-31	$131.65M	-0.13%
2023-09-30	$131.83M	13.11%
2023-06-30	$116.55M	9.14%
2023-03-31	$106.79M	13.32%
2022-12-31	$94.23M	12.42%
2022-09-30	$83.82M	13.49%
2022-06-30	$73.86M	14.54%
2022-03-31	$64.48M	5.82%
2021-12-31	$60.93M	17.03%
2021-09-30	$52.06M	7.07%
2021-06-30	$48.63M	-10.81%
2021-03-31	$54.52M	-4.77%
2020-12-31	$57.25M	8.07%
2020-09-30	$52.98M	9.30%
2020-06-30	$48.47M	-2.62%
2020-03-31	$49.77M	3.77%
2019-12-31	$47.97M	-6.57%
2019-09-30	$51.34M	-5.56%
2019-06-30	$54.36M	2.78%
2019-03-31	$52.89M	-7.41%
2018-12-31	$57.12M	12.66%
2018-09-30	$50.70M	7.27%
2018-06-30	$47.27M	1.69%
2018-03-31	$46.48M	-1.70%
2017-12-31	$47.29M	-1.82%
2017-09-30	$48.16M	7.60%
2017-06-30	$44.76M	22.21%
2017-03-31	$36.63M	-4.13%
2016-12-31	$38.20M	-0.83%
2016-09-30	$38.52M	22.94%
2016-06-30	$31.34M	52.45%
2016-03-31	$20.55M	13.97%
2015-12-31	$18.04M	-9.70%
2015-09-30	$19.97M	2.34%
2015-06-30	$19.52M	3.81%
2015-03-31	$18.80M	-10.64%
2014-12-31	$21.04M	20.99%
2014-09-30	$17.39M	161.58%
2014-06-30	$6.65M	-39.01%
2014-03-31	$10.90M	3.48%
2013-12-31	$10.53M	34.41%
2013-09-30	$7.84M	27.39%
2013-06-30	$6.15M	4141.27%
2013-03-31	$145.04K	-92.63%
2012-12-31	$1.97M	1682.50%
2012-09-30	$110.38K	1.47%
2012-06-30	$108.78K	-4.58%
2012-03-31	$114.00K	-0.33%
2011-12-31	$114.37K	-37.43%
2011-09-30	$182.78K	125.65%
2011-06-30	$81.00K	42.11%
2011-03-31	$57.00K	-60.15%
2010-12-31	$143.03K	178.65%
2010-09-30	$51.33K	100.00%
2010-06-30	-	-100.00%
2010-03-31	$2.28M	114.28%
2009-12-31	$1.06M	10040.78%
2009-09-30	$10.49K	-90.89%
2009-06-30	$115.16K	68.30%
2009-03-31	$68.43K	-98.10%
2008-12-31	$3.61M	4290.78%
2008-09-30	$82.21K	217.80%
2008-06-30	$25.87K	-43.27%
2008-03-31	$45.60K	-86.15%
2007-12-31	$329.21K	-

ANI Pharmaceuticals generated $148.33M in revenue during Q3 2024, up 7.46% compared to the previous quarter, and up 127.27% compared to the same period a year ago.

ANI Pharmaceuticals Revenue Breakdown

ANI Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Sales of generic pharmaceutical products	$269.45M	$210.12M	$143.57M	-	-
Sales of rare disease pharmaceutical products	$112.12M	$41.69M	-	-	-
Sales of established brand pharmaceutical products	$105.25M	$39.46M	-	-	-
Other	-	$693.00K	$1.86M	-	-
Product development services	-	$2.95M	$1.31M	-	-
Sales of contract manufactured products	-	$4.30M	$3.80M	-	-
Royalties from licensing agreements	-	$5.37M	$11.79M	-	-
Sales of branded pharmaceutical products	-	-	$47.56M	-	-
Other Revenues	-	-	-	$783.00K	-
Sales Of Branded Pharmaceutical Products	-	-	-	$47.96M	-
Royalties From Licensing Agreements	-	-	-	$1.40M	-
Product Development Services	-	-	-	$1.86M	-
Sales Of Generic Pharmaceutical Products	-	-	-	$147.26M	-
Sales Of Contract Manufactured Products	-	-	-	$6.80M	$8.10M
Products Development Services	-	-	-	-	$1.30M
Performance Obligation From Prior Period	-	-	-	-	$10.20M

ANI Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Sales of generic pharmaceutical products (55.35%), Sales of rare disease pharmaceutical products (23.03%), and Sales of established brand pharmaceutical products (21.62%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Unapproved Products	$5.50M	$4.40M	$4.70M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales of generic pharmaceutical products	-	$70.22M	$142.42M	$63.32M	$63.71M	$58.02M	$53.14M	$49.86M	$49.11M	$41.62M	-	-	-	-	-	-	-	-	-	-
Sales of rare disease pharmaceutical products	-	$36.94M	$71.48M	$24.30M	$16.33M	$17.59M	$12.60M	$10.20M	$1.29M	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	$63.00K	$164.00K	$213.00K	$253.00K	$289.00K	-	-	-	-	-	-	-	-	-	-
Product development services	-	-	-	-	-	$349.00K	$1.50M	$531.00K	$566.00K	$978.00K	-	-	-	-	-	-	-	-	-	-
Royalties from licensing agreements	-	-	-	-	-	$1.45M	$1.82M	$194.00K	$1.90M	$585.00K	-	-	-	-	-	-	-	-	-	-
Sales of contract manufactured products	-	-	-	-	-	$4.03M	$7.50M	$7.20M	$6.20M	$2.77M	-	-	-	-	-	-	-	-	-	-
Sales of established brand pharmaceutical products	-	-	-	-	-	$12.73M	$9.82M	$8.46M	$8.45M	-	-	-	-	-	-	-	-	-	-	-
Sales of branded pharmaceutical products	-	-	-	-	-	-	-	-	-	$14.69M	-	-	-	-	-	-	-	-	-	-
Royalties From Licensing Agreements	-	-	-	-	-	-	-	-	-	-	-	-	$11.21M	$276.00K	$339.00K	$491.00K	$-251.00K	-	-	-
Other Revenues	-	-	-	-	-	-	-	-	-	-	$149.00K	$969.00K	$75.00K	$265.00K	$76.00K	$161.00K	$259.00K	-	-	-
Product Development Services	-	-	-	-	-	-	-	-	-	-	$77.00K	$97.00K	$158.00K	$107.00K	$289.00K	$885.00K	$411.00K	-	-	-
Sales Of Branded Pharmaceutical Products	-	-	-	-	-	-	-	-	-	-	$14.31M	$11.04M	$7.52M	$15.76M	$12.41M	$10.63M	$14.00M	-	-	-
Sales Of Contract Manufactured Products	-	-	-	-	-	-	-	-	-	-	$3.00M	$3.60M	$6.30M	$2.19M	$7.80M	$5.80M	$2.64M	$5.50M	-	-
Sales Of Generic Pharmaceutical Products	-	-	-	-	-	-	-	-	-	-	$35.14M	$34.20M	$32.99M	$38.65M	$37.71M	$33.40M	$36.26M	-	-	-
Performance Obligation From Prior Period	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$16.70M	-	-

ANI Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Unapproved Products (100.00%).

ANI Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
CANADA	$565.00K	-	-	-	-
UNITED STATES	$486.25M	-	-	-	-
Canada	-	$3.96M	$4.24M	$6.88M	-
United States	-	$312.43M	$211.89M	$199.66M	-
C	-	-	-	$5.59M	-
U	-	-	-	$202.88M	-

ANI Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (99.88%), and CANADA (0.12%).

Quarterly Revenue by Country

Country	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Non-US	$1.22M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
UNITED STATES	$147.12M	$137.43M	$369.70M	$116.55M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CANADA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
United States	-	-	-	-	$106.22M	$93.00M	$82.85M	$72.81M	$63.76M	$59.89M	$48.23M	$46.58M	$50.03M	$52.14M	-	-	-	-	-	-
Canada	-	-	-	-	$565.00K	$1.23M	$970.00K	$1.04M	$717.00K	$1.04M	$1.54M	$1.39M	$1.31M	$2.21M	-	-	-	-	-	-
U	-	-	-	-	-	-	-	-	-	-	$51.10M	$47.58M	$53.33M	$56.28M	$52.09M	$46.28M	-	-	-	-
C	-	-	-	-	-	-	-	-	-	-	$961.00K	$1.04M	$1.19M	$973.00K	$885.00K	$2.19M	-	-	-	-

ANI Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (99.18%), and Non-US (0.82%).

ANI Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RDY	Dr. Reddy's Laboratories	$279.16B	-
NBIX	Neurocrine Biosciences	$1.89B	$622.10M
ALKS	Alkermes	$1.66B	$378.14M
PBH	Prestige Consumer Healthcare	$1.13B	$283.55M
PAHC	Phibro Animal Health	$977.89M	$273.16M
PCRX	Pacira BioSciences	$674.98M	$168.57M
AMPH	Amphastar Pharmaceuticals	$593.24M	$188.82M
COLL	Collegium Pharmaceutical	$566.77M	$159.30M
ANIP	ANI Pharmaceuticals	$486.82M	$148.33M
IRWD	Ironwood Pharmaceuticals	$442.74M	$91.59M
PROC	Procaps Group	$409.92M	$118.41M
INCR	InterCure	$355.55M	$73.47M
EGRX	Eagle Pharmaceuticals	$316.61M	$64.65M
DCPH	Deciphera Pharmaceuticals	$163.36M	$45.00M
SSIC	Silver Spike Investment	$11.72M	$2.76B

ANIP Revenue FAQ

What is ANI Pharmaceuticals’s yearly revenue?

ANI Pharmaceuticals's yearly revenue for 2023 was $486.82M, representing an increase of 53.87% compared to 2022. The company's yearly revenue for 2022 was $316.38M, representing an increase of 46.38% compared to 2021. ANIP's yearly revenue for 2021 was $216.14M, representing an increase of 3.67% compared to 2020.

What is ANI Pharmaceuticals’s quarterly revenue?

ANI Pharmaceuticals's quarterly revenue for Q3 2024 was $148.33M, a 7.46% increase from the previous quarter (Q2 2024), and a 12.52% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $138.04M, a 0.44% increase from the previous quarter (Q1 2024), and a 18.44% increase year-over-year (Q2 2023). ANIP's quarterly revenue for Q1 2024 was $137.43M, a 4.39% increase from the previous quarter (Q4 2023), and a 28.70% increase year-over-year (Q1 2023).

What is ANI Pharmaceuticals’s revenue growth rate?

ANI Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 125.24%, and for the last 5 years (2019-2023) was 135.69%.

What are ANI Pharmaceuticals’s revenue streams?

ANI Pharmaceuticals's revenue streams in c 23 are Sales of generic pharmaceutical products, Sales of rare disease pharmaceutical products, and Sales of established brand pharmaceutical products. Sales of generic pharmaceutical products generated $269.45M in revenue, accounting 55.35% of the company's total revenue, up 28.24% year-over-year. Sales of rare disease pharmaceutical products generated $112.12M in revenue, accounting 23.03% of the company's total revenue, up 168.96% year-over-year. Sales of established brand pharmaceutical products generated $105.25M in revenue, accounting 21.62% of the company's total revenue, up 166.71% year-over-year.

What is ANI Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of ANI Pharmaceuticals was Sales of generic pharmaceutical products. This segment made a revenue of $269.45M, representing 55.35% of the company's total revenue.